Evidence map›Paper›PMID 23352199›Full record

Trial reportThe Lancet. Neurology2013

Fetal antiepileptic drug exposure and cognitive outcomes at age 6 years (NEAD study): a prospective observational study.

Kimford J Meador, Gus A Baker, Nancy Browning, Morris J Cohen, Rebecca L Bromley, Jill Clayton-Smith, Laura A Kalayjian, Andres Kanner, Joyce D Liporace, Page B Pennell and 3 more

Registry-linked trialOpen access · greenAbstract readClinical TrialComparative StudyMulticenter Study
In one paragraph

Trial report in The Lancet. Neurology, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT00021866 (Neurodevelopmental Effects of Antiepileptic Drugs II), which is not on this map. Cited by 239 papers, 9 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
239citing papers in PubMed, 9 pooled it
114.9field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT00021866 completednot on this map

Neurodevelopmental Effects of Antiepileptic Drugs II: the NEAD Study

TypeobservationalSponsorEmory UniversityRan2000 to 2012Enrolled331ConditionsEpilepsy, Seizure, Cognition DisordersArmsDifferential Abilities Scale, Neuropsychological Testing
3 · Its place in the literature

Who cites it

239 citing papers in PubMed, 9 syntheses or guidelines pooled it, 823 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Pooled it
  4. Guideline
  5. Pooled it
  6. Pooled it
  7. Guideline
  8. Pooled it
  9. Management of adverse effects of mood stabilizers.Current psychiatry reports · 2015
    Pooled it
  10. Trial
  11. Observational
  12. Observational
  13. Review
  14. Article
  15. Article
  16. Article
  17. Review
  18. Observational
  19. Article
  20. Article

179 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

13 authors at 11 institutions in 2 countries.

Kimford J MeadorNeurology and Pediatrics, Emory University, Atlanta, GA 30322, USA. kimford.meador@emory.edu
Gus A Baker
Nancy Browning
Morris J Cohen
Rebecca L Bromley
Jill Clayton-Smith
Laura A Kalayjian
Andres Kanner
Joyce D Liporace
Page B Pennell
Michael Privitera
David W Loring
NEAD Study Group
Emory University · USAugusta University Health · USBrigham and Women's Hospital · USEmmes (United States) · USRiddle Hospital · USRush University Medical Center · USUniversity of Cincinnati · USUniversity of Liverpool · GBUniversity of Manchester · GBUniversity of Southern California · USWalton Centre · GB

Funding

Maternal Outcomes and Neurodevelopmental Effects of Antiepileptic Drugs (MONEAD)U01NS038455 · NINDS · STANFORD UNIVERSITY · PI MATTHEWS, ABIGAIL GOREN, MEADOR, KIMFORD J · 2012 to 2022
$27.7M
NEURODEVELOPMENT EFFECTS OF ANTIEPILEPTIC DRUGSR01NS038455 · NINDS · UNIVERSITY OF FLORIDA · PI MEADOR, KIMFORD J · 2000 to 2009
$12.0M
MONEAD Data and Statistical CenterU01NS050659 · NINDS · THE EMMES COMPANY, LLC · PI MAY, RYAN · 2012 to 2016
$3.5M
Neurodevelopment Effects of Antiepileptic DrugsR01NS050659 · NINDS · THE EMMES COMPANY, LLC · PI BROWNING, NANCY · 2004 to 2008
$2.5M
NINDS NIH HHS NS038455NINDS NIH HHS NS050659NINDS NIH HHS R01 NS038455NINDS NIH HHS R01 NS050659NINDS NIH HHS U01 NS038455NINDS NIH HHS U01 NS050659
6 · The paper itself

Abstract

backgroundMany women of childbearing potential take antiepileptic drugs, but the cognitive effects of fetal exposure are uncertain. We aimed to assess effects of commonly used antiepileptic drugs on cognitive outcomes in children up to 6 years of age.

methodsIn this prospective, observational, assessor-masked, multicentre study, we enrolled pregnant women with epilepsy on antiepileptic drug monotherapy (carbamazepine, lamotrigine, phenytoin, or valproate) between October, 1999, and February, 2004, at 25 epilepsy centres in the UK and the USA. Our primary outcome was intelligence quotient (IQ) at 6 years of age (age-6 IQ) in all children, assessed with linear regression adjusted for maternal IQ, antiepileptic drug type, standardised dose, gestational birth age, and use of periconceptional folate. We also assessed multiple cognitive domains and compared findings with outcomes at younger ages. This study is registered with ClinicalTrials.gov, number NCT00021866.

findingsWe included 305 mothers and 311 children (six twin pairs) in the primary analysis. 224 children completed 6 years of follow-up (6-year-completer sample). Multivariate analysis of all children showed that age-6 IQ was lower after exposure to valproate (mean 97, 95% CI 94-101) than to carbamazepine (105, 102-108; p=0·0015), lamotrigine (108, 105-110; p=0·0003), or phenytoin (108, 104-112; p=0·0006). Children exposed to valproate did poorly on measures of verbal and memory abilities compared with those exposed to the other antiepileptic drugs and on non-verbal and executive functions compared with lamotrigine (but not carbamazepine or phenytoin). High doses of valproate were negatively associated with IQ (r=-0·56, p<0·0001), verbal ability (r=-0·40, p=0·0045), non-verbal ability (r=-0·42, p=0·0028), memory (r=-0·30, p=0·0434), and executive function (r=-0·42, p=0·0004), but other antiepileptic drugs were not. Age-6 IQ correlated with IQs at younger ages, and IQ improved with age for infants exposed to any antiepileptic drug. Compared with a normative sample (173 [93%] of 187 children), right-handedness was less frequent in children in our study overall (185 [86%] of 215; p=0·0404) and in the lamotrigine (59 [83%] of 71; p=0·0287) and valproate (38 [79%] of 40; p=0·0089) groups. Verbal abilities were worse than non-verbal abilities in children in our study overall and in the lamotrigine and valproate groups. Mean IQs were higher in children exposed to periconceptional folate (108, 95% CI 106-111) than they were in unexposed children (101, 98-104; p=0·0009).

interpretationFetal valproate exposure has dose-dependent associations with reduced cognitive abilities across a range of domains at 6 years of age. Reduced right-handedness and verbal (vs non-verbal) abilities might be attributable to changes in cerebral lateralisation induced by exposure to antiepileptic drugs. The positive association of periconceptional folate with IQ is consistent with other recent studies.

Indexed as

AdultAnticonvulsantsChildChild DevelopmentChild, PreschoolCognitionEpilepsyFemaleHumansInfantInfant, NewbornLamotrigineMaleObservationPhenytoinPregnancyAnticonvulsantsLamotriginePhenytoinTriazines

Identifiers

PMID23352199
PMCPMC3684942
OpenAlexW1983142641

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.